Clinical trial
A Phase 1b, Single-Center, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Mosquitocidal Activity of Single Oral Doses of Lotilaner in Healthy Participants in Mali.
NCT07758985 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Single-Center, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Mosquitocidal Activity of Single Oral Doses of Lotilaner in Healthy Participants in Mali.
- Lead sponsor
- Medicines for Malaria Venture
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 14, 2026
- Completion date
- August 31, 2027
- Enrollment
- 75 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.